

Prior Authorization DRUG Guidelines

Corifact® (Factor XIII Concentrates)

Effective Date: 1/31/12

Date Developed: 12/9/11 by Albert Reeves MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

Corifact is an Antihemophilic Agent; Blood Product Derivative. Factor XIII replaces Proteins to stop bleeding.

Pre-Authorization Criteria: prophylaxis against bleeding episodes and management of perioperative surgical bleeding in patients with congenital factor XIII deficiency

Note:

VCHCP requires that Cortifact is prescribed by a Hematologist.

Dosing: ADULTS:

Congenital factor XIII deficiency prophylaxis: I.V.: Initial: 40 units/kg

Maintenance: Dose adjustment based on factor XIII trough levels (target level of 5% to 20% using Berichrom® activity assay) and clinical response; repeat every 4 weeks:

One trough level of <5%: Increase dosage by 5 units/kg

Trough level of 5% to 20%: No dosage change

Two trough levels of >20%: Decrease dosage by 5 units/kg

One trough level of >25%: Decrease dosage by 5 units/kg

Dosing: Pediatric

Refer to adult dosing.

Dosing: Geriatric

Refer to adult dosing.

Dosage Forms

Injection, powder for reconstitution: Corifact®: Exact potency labeled on each vial [heat treated; supplied with diluent]

Administration

Administer by I.V. infusion at a rate not to exceed 4 mL/minute. Product should be brought to room temperature prior to infusing. Administer through a separate infusion line

WARNINGS / PRECAUTIONS

Concerns related to adverse effects:

Antibody formation: The development of factor XIII inhibitory antibodies has been reported. Factor XIII inhibitory antibodies should be measured when clinical response (breakthrough bleeding) and/or factor XIII trough levels are suboptimal after apparent adequate dosing.

Hypersensitivity reactions: Hypersensitivity and anaphylactic reactions have been reported with use; discontinue immediately if develops.

Thrombotic events: Thromboembolic events have been reported; pregnant women may be at increased risk due to hypercoagulable state.

DRUG Interactions

There are no known significant interactions.

REFERENCES

1. Hsieh L and Nugent D, "Factor XIII Deficiency," *Haemophilia*, 2008, 14(6):1190-200.
2. Karimi M, Bereczky Z, Cohan N, et al, "Factor XIII Deficiency," *Semin Thromb Hemost*, 2009, 35(4):426-38. [PubMed [19598071](#)]

Select Drug Information from [Lexi-Comp Online](#)™
Copyright (1978 to present) Lexi-Comp, Inc.

Epocrates 2013 – [www.epocrates.com](#)

©2013 UpToDate® - [www.uptodate.com](#)

Revision History:

Date Reviewed/No Updates: 1/16/13 by A. Reeves MD
Date Approved by P&T Committee: 1/31/12; 1/29/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review